BACKGROUND: Standard risk factors do not adequately capture cardiovascular risk in postmenopausal women. We sought to determine the associations between levels of sex steroids and levels of inflammatory markers in postmenopausal women. METHODS: We analyzed baseline data from a subset of postmenopausal women aged 45-64 years who had stored samples during a randomized controlled trial. We measured levels of C-reactive protein (CRP), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), soluble intercellular adhesion molecule (sICAM), and circulating sex steroids. Multiple linear regression models were created with each of the following hormone levels as the primary exposure variable: estrone, total estradiol, bioavailable estradiol, total testosterone, bioavailable testosterone, progesterone, and sex hormone-binding globulin (SHBG). Sociodemographic and lifestyle covariates were derived from standardized self-report questionnaires and direct measurement (weight, height). RESULTS: Mean age of the 623 women was 56 years. After adjustment for age, body mass index (BMI), physical activity, alcohol consumption, and smoking, the bioavailable testosterone level (p = 0.03) was positively and the SHBG level (p < 0.001) was negatively associated with the logCRP level. The increment in CRP level between the highest and lowest quartile of bioavailable testosterone was 1.28 microg/mL. The increment in CRP level between the lowest and highest quartile of SHBG was 2.62 microg/mL. Compared with SHBG or bioavailable testosterone as predictors of logCRP in separate regression models, when both SHBG and bioavailable testosterone were included in the same multivariate linear regression model, only SHBG remained a statistically significant predictor of logCRP. Progesterone level was positively associated with the logMMP-9 level (p < 0.001); no other sex steroid level was associated with the logMMP-9 level. In multiply adjusted models, no association was found between levels of any sex steroid and IL-6 or sICAM level.
BACKGROUND: Standard risk factors do not adequately capture cardiovascular risk in postmenopausal women. We sought to determine the associations between levels of sex steroids and levels of inflammatory markers in postmenopausal women. METHODS: We analyzed baseline data from a subset of postmenopausal women aged 45-64 years who had stored samples during a randomized controlled trial. We measured levels of C-reactive protein (CRP), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), soluble intercellular adhesion molecule (sICAM), and circulating sex steroids. Multiple linear regression models were created with each of the following hormone levels as the primary exposure variable: estrone, total estradiol, bioavailable estradiol, total testosterone, bioavailable testosterone, progesterone, and sex hormone-binding globulin (SHBG). Sociodemographic and lifestyle covariates were derived from standardized self-report questionnaires and direct measurement (weight, height). RESULTS: Mean age of the 623 women was 56 years. After adjustment for age, body mass index (BMI), physical activity, alcohol consumption, and smoking, the bioavailable testosterone level (p = 0.03) was positively and the SHBG level (p < 0.001) was negatively associated with the logCRP level. The increment in CRP level between the highest and lowest quartile of bioavailable testosterone was 1.28 microg/mL. The increment in CRP level between the lowest and highest quartile of SHBG was 2.62 microg/mL. Compared with SHBG or bioavailable testosterone as predictors of logCRP in separate regression models, when both SHBG and bioavailable testosterone were included in the same multivariate linear regression model, only SHBG remained a statistically significant predictor of logCRP. Progesterone level was positively associated with the logMMP-9 level (p < 0.001); no other sex steroid level was associated with the logMMP-9 level. In multiply adjusted models, no association was found between levels of any sex steroid and IL-6 or sICAM level.
Authors: Tracy E Madsen; Xi Luo; Mengna Huang; Ki E Park; Marcia L Stefanick; JoAnn E Manson; Simin Liu Journal: Stroke Date: 2020-02-12 Impact factor: 7.914
Authors: Ronald C Eldridge; Nicolas Wentzensen; Ruth M Pfeiffer; Louise A Brinton; Patricia Hartge; Chantal Guillemette; Troy J Kemp; Ligia A Pinto; Britton Trabert Journal: Cancer Causes Control Date: 2020-02-25 Impact factor: 2.506
Authors: Marcello Maggio; Gian Paolo Ceda; Fulvio Lauretani; Stefania Bandinelli; Anna Maria Corsi; Francesco Giallauria; Jack M Guralnik; Giovanni Zuliani; Chiara Cattabiani; Stefano Parrino; Fabrizio Ablondi; Elisabetta Dall'aglio; Graziano Ceresini; Shehzad Basaria; Luigi Ferrucci Journal: J Clin Endocrinol Metab Date: 2011-01-14 Impact factor: 5.958
Authors: Marcello Maggio; Fulvio Lauretani; Gian Paolo Ceda; Stefania Bandinelli; Shehzad Basaria; Giuseppe Paolisso; Alessandro Ble; Josephine M Egan; E Jeffrey Metter; Angela M Abbatecola; Giovanni Zuliani; Carmelinda Ruggiero; Giorgio Valenti; Jack M Guralnik; Luigi Ferrucci Journal: Am J Physiol Endocrinol Metab Date: 2006-09-12 Impact factor: 4.310
Authors: Genevieve A Woodard; Vinay G Mehta; Rachel H Mackey; Ping Tepper; Sheryl F Kelsey; Anne B Newman; Kim Sutton-Tyrrell Journal: Menopause Date: 2011-12 Impact factor: 2.953
Authors: Roksana Karim; Frank Z Stanczyk; Howard N Hodis; Mary Cushman; Roger A Lobo; Juliana Hwang; Wendy J Mack Journal: Menopause Date: 2010-07 Impact factor: 2.953